Peptide Reference
ACE-031
Activin Receptor Type IIB-Fc
A fusion protein that inhibits myostatin and related proteins by binding to activin receptors. Developed for muscular dystrophy treatment.
Status
clinical discontinued
Category
muscle
Typical cost
Not commercially available
Mechanism
Binds to activin type IIB receptors, blocking myostatin and related growth factors from exerting their muscle-limiting effects. Results in rapid and substantial muscle growth beyond normal genetic limits.
Potential benefits
- Rapid muscle growth
- Dramatic strength increases
- Muscle disease treatment potential
Reported side effects
- Nosebleeds
- Skin telangiectasia
- Gum bleeding
- Safety concerns halted development
Common dosing references
subcutaneous
1-3mg/kg · Weekly
Clinical trial dosing
Research notes
ACE-031 in muscular dystrophy
2013
Demonstrated significant lean mass increases but trials halted due to safety concerns
Regulatory and sourcing notes
Clinical trials halted due to safety concerns (nosebleeds, skin changes). Not approved. Research chemical status.
Not recommended due to documented safety issues. Development discontinued.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides